It doesn’t seem that long ago when putting tiny machines into people’s bodies to cure or manage diseases was the stuff of science-fiction, but bioelectronics is a real – if very new – field of medicine. Alphabet’s Verily Life Sciences (formerly Google Life Sciences) and pharma company GSK are teaming up to invest $715M in the tech over the next seven years.

Bioelectronic medicine is a relatively new scientific field that aims to tackle a wide range of chronic diseases using miniaturised, implantable devices that can modify electrical signals that pass along nerves in the body, including irregular or altered impulses that occur in many illnesses. GSK has been active in this field since 2012 and believes certain chronic conditions such as arthritis, diabetes and asthma could potentially be treated using these devices … 

expand full story